The KRAS mutation phenotype (mutant or wild-type) has been used successfully for treatment decisions for anti-EGFR treatment in colorectal cancer: patients with KRAS mutations benefited significantly less from anti-EGFR treatment than patients with KRAS wild-type tumors49. This evidence concerns the gene KRAS and colorectal cancer.